Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens.
BACKGROUND:Genetic variants of inosine triphosphatase (ITPA) that confer reduced ITPase activity are associated with protection against ribavirin(RBV)-induced hemolytic anemia in peginterferon(IFN)/RBV-based treatment of hepatitis C virus (HCV). Patients with reduced ITPase activity showed improved...
Main Authors: | Aparna Vasanthakumar, Justin W Davis, Manal Abunimeh, Jonas Söderholm, Jiuhong Zha, Emily O Dumas, Daniel E Cohen, Jeffrey F Waring, Martin Lagging |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5979032?pdf=render |
Similar Items
-
ITPase deficiency causes a Martsolf-like syndrome with a lethal infantile dilated cardiomyopathy.
by: Mark T Handley, et al.
Published: (2019-03-01) -
Predictors of anemia associated with pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C
by: Ta-Wei Chen, et al.
Published: (2011) -
Chronic hepatitis C successfully treated with telaprevir, pegylated interferon and ribavirin in severe aplastic anemia
by: Ilker I. Balkan, et al.
Published: (2014-11-01) -
Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment
by: Geng-lin Zhang, et al.
Published: (2017-01-01) -
Influencing factors for hemolytic anemia in patients with chronic hepatitis C treated by ribavirin combined with pegylated interferon-α
by: XU Jinfeng
Published: (2019-02-01)